Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Endogenous Opioid Modulation in MDD
NCT03051945Phase 3Withdrawn
- Sponsor
- University of Utah
- Start
- Aug 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine in major depressive disorder (MDD), sponsored by University of Utah. Primary endpoint: Hamilton Depression Rating Scale at 24 hours. Planned start Aug 2019; status: withdrawn.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03051945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051945.